HR Execs on the Move

Friendship Health and Rehab Center

www.friendship.us.com

 
Friendship Health and Rehab Center is a Roanoke, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 50K-100K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Clintech Research

Clintech Research is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CE and IC Inc

CE & IC Inc is a Burlington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTCâ„¢) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICAâ„¢ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Scifluor Life Sciences

SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics. The company is creating a portfolio of new chemical entities (NCEs) directed towards precedented biological targets. SciFluor strategically incorporates fluorine or fluorine-containing groups to design drugs with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, more convenient dosing and better patient compliance. This capital-efficient and de-risked drug discovery approach has resulted in the generation of a proprietary pipeline of novel and differentiated small molecule drugs across a range of therapeutic categories and disease areas including retinal disease, CNS disorders, fungal and bacterial infections and inflammatory disease.

Center des Research Hotel-Dieu, U Laval

Center des Research Hotel-Dieu, U Laval is a Quí©bec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.